Literature DB >> 27889596

Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.

Lukas Schwentner1, Gisela Helms2, Valentina Nekljudova3, Beyhan Ataseven4, Ingo Bauerfeind5, Nina Ditsch6, Tanja Fehm7, Barbara Fleige8, Maik Hauschild9, J Heil10, Sherko Kümmel11, Anette Lebeau12, Sabine Schmatloch13, Peter Schrenk14, Anette Staebler15, Sibylle Loibl3, Michael Untch16, Gunter Von Minckwitz3, Cornelia Liedtke17, Thorsten Kühn18.   

Abstract

BACKGROUND: With the growing importance of neoadjuvant systemic therapy (NST) the assessment of post neoadjuvant axillary status is of increasing importance especially in patients who presented initially with suspicious nodes (cN1). This study aims to investigate the predictive value of palpation and axillary ultrasound of formerly cN1 patients following NST. PATIENTS AND METHODS: The SENTINA trial (SENTinel NeoAdjuvant) is a 4-arm prospective multicenter study designed to evaluate the role of sentinel node biopsy (SLNB) in the context of neoadjuvant systemic treatment (NST) of breast cancer patients.
RESULTS: 1240 patients from 103 institutions entered the trial. 715 (arm C n = 592; arm D n = 123) patients, who presented initially cN1 underwent clinical evaluation of lymph node status following NST. Palpation alone demonstrated a sensitivity of 8.3%, specifity of 94.8% and a negative predictive value (NPV) of 46.6%. Ultrasound alone revealed a sensitivity of 23.9%, specificity 91.7%, and a NPV of 50.3%.The investigators combined classification (palpation and ultrasound) resulted in a sensitivity of 24.4%, specificity 91.4%, and a NPV of 50.3%. Investigators classified the axilla nodes as being unsuspicious (cN0) following NST in 592/715 patients; of them 298 (50.3%) were pN0, 151 (25.5%) had 1-2 histologically involved nodes and 143 (24.2%) had >2 histologically involved nodes.
CONCLUSION: The diagnostic accuracy of ultrasound and palpation following NST is unacceptably low and additional tools for evaluation of the axillary lymph node status following NST are urgently needed.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Axillary ultrasound; Breast cancer; Neoadjuvant chemotherapy; Sentinel-node-biopsy

Mesh:

Year:  2016        PMID: 27889596     DOI: 10.1016/j.breast.2016.11.012

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  12 in total

1.  Predictive factors of an axillary pathological complete response of node-positive breast cancer to neoadjuvant chemotherapy.

Authors:  Naoko Iwamoto; Tomoyuki Aruga; Shinichiro Horiguchi; Chiaki Saita; Mai Onishi; Risa Goto; Toshiyuki Ishiba; Yayoi Honda; Hiromi Miyamoto; Katsumasa Kuroi
Journal:  Surg Today       Date:  2019-07-31       Impact factor: 2.549

Review 2.  Imaging Considerations and Interprofessional Opportunities in the Care of Breast Cancer Patients in the Neoadjuvant Setting.

Authors:  Anna G Sorace; Sara Harvey; Anum Syed; Thomas E Yankeelov
Journal:  Semin Oncol Nurs       Date:  2017-09-15       Impact factor: 2.315

3.  Feasibility of fine-needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study.

Authors:  Abigail S Caudle; Henry M Kuerer; Savitri Krishnamurthy; Kyungmin Shin; Brian P Hobbs; Junsheng Ma; Elizabeth A Mittendorf; Ashley C Washington; Sarah M DeSnyder; Dalliah M Black; Kelly K Hunt; Wei T Yang
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

4.  Application of the Z1071 criteria: classification of axillary lymph nodes on ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer.

Authors:  Naoko Iwamoto; Hiromi Miyamoto; Shinichiro Horiguchi; Yayoi Honda; Tomoyuki Aruga
Journal:  J Med Ultrason (2001)       Date:  2020-02-29       Impact factor: 1.314

5.  Is Clinical Exam of the Axilla Sufficient to Select Node-Positive Patients Who Downstage After NAC for SLNB? A Comparison of the Accuracy of Clinical Exam Versus MRI.

Authors:  Tracy-Ann Moo; Maxine S Jochelson; Emily C Zabor; Michelle Stempel; Monica Raiss; Anita Mamtani; Audree B Tadros; Mahmoud El-Tamer; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2019-10-03       Impact factor: 5.344

6.  Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members.

Authors:  Abigail S Caudle; Isabelle Bedrosian; Denái R Milton; Sarah M DeSnyder; Henry M Kuerer; Kelly K Hunt; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

7.  Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype.

Authors:  Yurina Maeshima; Takehiko Sakai; Akiko Ogiya; Yoko Takahashi; Yumi Miyagi; Yumi Kokubu; Tomo Osako; Yoshinori Ito; Shunji Takahashi; Shinji Ohno; Takayuki Ueno
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

8.  Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.

Authors:  Won Hwa Kim; Sang-Woo Lee; Hye Jung Kim; Yee Soo Chae; Shin Young Jeong; Jin Hyang Jung; Ho Yong Park; Won Kee Lee
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

9.  Practical consensus recommendations for tumor margins and breast conservative surgery.

Authors:  R Sarin; S P Somsekhar; R Kumar; Gupta Pawan; Jain Sumeet; Jindal Pramoj; Zamre Vaishali; Pasha Firoz; P M Parikh; S Aggarwal; R Koul
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun

10.  Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.

Authors:  Signe Borgquist; Lisa Rydén; Ida Skarping; Daniel Förnvik; Sophia Zackrisson
Journal:  Breast Cancer Res Treat       Date:  2021-06-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.